Myocardial Infarction (MI) 3-in-1 Test Kit (Immunofluorescence) is mainly for the in vitro quantitative determination of cardiac Troponin I (cTnI), Creatine Kinase-MB (CK-MB), Myoglobin (MYO) content in human serum. Cardiac Troponin I (cTnI) as one of the units of cardiac troponin (cTn), only exists in the atrial and ventricular myocytes, when myocardial cell membrane is complete, cTnI cannot penetrate the cell membrane into the blood circulation; when myocardial cells become necrosis due to ischemia or hypoxia, cTnI can enter the cytoplasm through damaged cell membrane, then enter the bloodstream, so cTnI can be used as an acute diagnostic index for acute myocardial infarction (AMI). As one of the three isoenzymes of creatine kinase (CK), CK-MB is mainly located in the myocardium, and has 20% activity of CK. CK-MB is an important index in the diagnosis of acute myocardial infarction (AMI), which is largely secreted into the blood when the AMI attacks, the concentration of CK-MB rises as early as 3 to 6 hours after onset, peaks

at between 12 and 24 hours, and returns to normal after 3 days, if there are complications, serum CK-MB concentration will maintain at a high level, if AMI happens again, CK-MB will rise again. Myoglobin (MYO) is an oxygen-binding heme protein, mainly distributed

in the cardiac and skeletal muscle. Myoglobin releases into the circulation as early as 2 to 3 hours after acute myocardial injury, peaks at between 9 and 12 hours, and returns to normal within 24 to 36 hours. It is recommended to sample and detect continuously for patients with acute coronary syndrome (ACS), because there is a delay between symptom appearing and blood releasing of protein makers. MYO negative is helpful to eliminate AMI, so myoglobin is one of the most important indexes for early diagnosis of AMI, and is widely used in the diagnosis of AMI, prognosis judgment and disease prediction.